Prokaryotics, Inc. entered into a worldwide licensing agreement with Merck & Co Inc. for novel investigational antibiotic candidates. Under the agreement, Prokaryotics gains worldwide rights to develop, manufacture and commercialize a collection of early pre-clinical programs and compounds with potential application as novel antibiotics targeting Gram-negative and Gram-positive bacterial cell envelope enzymes. This agreement enables Prokaryotics and Merck to develop investigational antibiotic candidates.